

type of report	Current report
number	47/2012
date of publication	2012-08-24 10:47:13
company	PHARMENA

Entering into loan agreement with a member of Supervisory Board

The Management Board of PHARMENA S.A. informs that on 23rd August 2012 it entered into a loan agreement with Prof Jerzy Gębicki – Chairman of Supervisory Board for the sum of 200,000 PLN (say: two hundred thousand PLN). The loan bears interest at 1M WIBOR plus a margin of 7% per annum. The loan agreement was signed for a 3-month period.

The above loan agreement was signed by the Management Board of PHARMENA S.A. pursuant to authorisation included in resolution no. 7 adopted by the Extraordinary General Meeting of 21st August 2012.

Entering into the agreement lies within the realisation of the Company's updated Strategy for 2012-2015 in the scope of research of innovative anti-atherosclerosis medicinal product 1-MNA (the Issuer informed about the strategy's assumptions in current report no. 16/2012 of 13th April 2012). Production of tablets containing active substance 1-MNA is necessary for carrying out further clinical trials in Canada. The goal of the loan is to ensure financial means for production of tablets for clinical trials on 1-MNA medicinal product until public offering of series C shares with pre-emptive rights is effected. It is planned to reimburse the loan from the funds obtained from series C shares offering.

The information is made public due to the fact that the company entered into a loan agreement with a member of the company's governing body. Moreover, the finalisation of the process of production of tablets is essential for the possibility to carry out further clinical trials on anti-atherosclerosis medicinal product and the commercialisation of this project. Potential revenue resulting from the commercialisation of anti-atherosclerosis medicinal product may have significant influence on the Issuer's future financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board